InsiderSignal.AI

InsiderSignal.ai

CTNM - Contineum Therapeutics, Inc.

Insider Sale by Lorrain Daniel S. (Chief Scientific Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Lorrain Daniel S., serving as Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 8,124 shares at $16.02 per share, for a total transaction value of $130,164.00. Following this transaction, Lorrain Daniel S. now holds 162,894 shares of CTNM.

This sale represents a 5.00% decrease in Lorrain Daniel S.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, February 24, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 26, 2026, 2 days after the trade was made.

Contineum Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lorrain Daniel S.

Chief Scientific Officer

Daniel S. Lorrain, Ph.D. is the Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), a role he has held since March 2018 as a founding executive.[[1]](https://fintool.com/app/research/companies/CTNM/people/daniel-lorrain) At 56 years old, he earned a B.S. in Psychology and a Ph.D. in Behavioral Neuroscience from SUNY Buffalo, followed by a postdoctoral fellowship at the University of Chicago.[[1]](https://fintool.com/app/research/companies/CTNM/people/daniel-lorrain) Dr. Lorrain's career highlights include serving as Executive Director and VP of Biology at Inception Therapeutics (2011–2018), where he led biology and non-clinical pharmacology for the remyelination program 'Inception 5,' acquired by Roche.[[1]](https://fintool.com/app/research/companies/CTNM/people/daniel-lorrain) Previously, as Senior Director of Pharmacology at Amira Pharmaceuticals (2005–2010), he drove the LPA1R program acquired by Bristol-Myers Squibb, and contributed to early CNS drug discovery as a Research Fellow at Merck & Co. (1999–2005).[[1]](https://fintool.com/app/research/companies/CTNM/people/daniel-lorrain) Recently, as a corporate insider, he executed sales of CTNM shares, including 4,170 shares on December 23, 2025, for $51,009 under a 10b5-1 plan, with total sales of 8,340 shares across three transactions.[[2]](https://www.ainvest.com/news/insider-sale-chief-scientific-officer-ctnm-sold-4-170-shares-2601/)[[4]](https://stockunlock.com/stockDetails/CTNM/insider/insiderTransactions)[[5]](https://www.investing.com/news/insider-trading-news/lorrain-contineum-therapeutics-cso-sells-51k-in-stock-93CH-4425878) He participates in the company's Executive Severance Plan and holds significant equity alignment through stock options.[[1]](https://fintool.com/app/research/companies/CTNM/people/daniel-lorrain)

View full insider profile →

Trade Price

$16.02

Quantity

8,124

Total Value

$130,164.00

Shares Owned

162,894

Trade Date

Tuesday, February 24, 2026

3 days ago

SEC Filing Date

Thursday, February 26, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Contineum Therapeutics, Inc.

Company Overview

No company information available
View news mentioning CTNM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4324851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime